Telix Pharmaceuticals (TLX) Goodwill (2024 - 2025)

Telix Pharmaceuticals (TLX) posted quarterly Goodwill of $199.0 million for Q4 2025, up 198.84% year-on-year from $66.6 million in Q4 2024, and up 198.84% on a QoQ basis from $66.6 million in Q4 2024.

Telix Pharmaceuticals (TLX) Goodwill (2024 - 2025) Analysis & Trends

Telix Pharmaceuticals (TLX) has reported Goodwill for 2 consecutive years, with $199.0 million the latest figure, recorded in Q4 2025.

  • Quarterly Goodwill rose 198.84% year-over-year to $199.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $199.0 million (up 198.84% YoY) and the FY2025 annual result came in at $199.0 million, up 198.84% from the prior year.
  • Goodwill rose to $199.0 million in Q4 2025 per TLX's latest filing, from $66.6 million in the prior quarter.
  • Over the last five years, Goodwill for TLX reached as high as $199.0 million in Q4 2025 and fell as low as $66.6 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Telix Pharmaceuticals 3.55 Bn 3.41 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2025 198.99 Mn
Dec 31, 2024 66.59 Mn